IP Library Granted Patent US 11,123,348
Granted Patent B2
US 11,123,348 · App. 16/780,628 · Granted Sep 21, 2021

Compounds and compositions for the treatment of parasitic diseases

Inventors: Agnes Biggart (Spring Valley, CA); Fang Liang (Encinitas, CA); Casey Jacob Nelson Mathison (San Diego, CA); Valentina Molteni (San Diego, CA); Advait Suresh Nagle (San Diego, CA); Frantisek Supek (San Diego, CA); Vince Yeh (San Diego, CA)
Assignee: Novartis AG
A61K31/519A61K31/5377A61K31/695A61K45/06C07D487/04C07D519/00C07F5/027C07F7/0814Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,123,348
App. No.
16/780,628
Granted
Sep 21, 2021
Kind
B2
Abstract

The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.

Claims (5)

1. A method for treating Chagas disease, comprising administering to a subject in need thereof a therapeutically effective amount of N-(4-fluoro-3-(6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide, or a pharmaceutically acceptable salt thereof; and optionally in combination with a second agent.

2. The method of claim 1 , wherein said second agent is benznidazole, nifurtimox, amphotericin or a combination thereof.

3. The method of claim 1 , wherein said second agent is benznidazole.

4. The method of claim 1 , wherein said second agent is nifurtimox.

5. The method of claim 1 , wherein said second agent is amphotericin.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2020
From: BIGGART, AGNES; LIANG, FANG; MATHISON, CASEY JACOB NELSON; MOLTENI, VALENTINA; NAGLE, ADVAIT SURESH; SUPEK, FRANTISEK; YEH, VINCE
To: NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION
Reel/Frame 052556/0588 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2020
From: NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION
To: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.
Reel/Frame 052556/0601 →
MERGER Recorded May 3, 2020
From: IRM LLC
To: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.
Reel/Frame 052556/0621 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2020
From: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.
To: NOVARTIS INTERNATIONAL PHARMACEUTICAL AG
Reel/Frame 052556/0623 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2020
From: NOVARTIS INTERNATIONAL PHARMACEUTICAL AG
To: NOVARTIS AG
Reel/Frame 052556/0632 →
Continuity (6)
Division 16116418 · Aug 29, 2018
Continuation 15600183 · May 19, 2017
Continuation 15051446 · Feb 23, 2016
Division 14574775 · Dec 18, 2014
Provisional Application 61918089 · Dec 19, 2013
Related Publication 20200179391A1 · Jun 11, 2020